News

IVS-3001, a chimeric antigen receptor therapy developed to target and kill HLA-G-bearing cells, is currently in late-stage preclinical development for the treatment of solid tumors.

Results from the CARTITUDE-2 trial of cilta-cel for multiple myeloma support the use of chimeric antigen receptor T-cell therapy earlier in therapy than what is currently approved.

KEYNOTE-756 is the first positive phase 3 study to generate a statistically significant improvement in pathological complete response rate with an immunotherapy regimen in the neoadjuvant setting for ER-positive/HER2-negative breast cancer.

FDA approval has been granted to dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair deficient and microsatellite instability-high primary advanced or recurrent endometrial cancer.

Although no safety or efficacy issues were reported in the biologics license application for denileukin diftitox for cutaneous T-cell lymphoma, a complete response letter has been issued.

The phase 3 QuANTUM-First trial showed that quizartinib plus chemotherapy with or without allogeneic hematopoietic stem cell transplant improved overall survival in patients with acute myeloid leukemia with a FLT3-ITD mutation.

ctDNA sequencing can efficiently detect KIT/PDGFRA mutations and predict outcomes in patients with tyrosine kinase inhibitor-resistant gastrointestinal stromal tumor treated with avapritinib.

Ghassan K. Abou-Alfa, MD, discusses the phase 3 RATIONALE-301 trial of frontline tislelizumab vs sorafenib in patients with hepatocellular carcinoma.

Phase 1 results with the KRAS G12C inhibitor garsorasib did not show an immediate advantage with the latest KRAS G12C inhibitor but show that investigations into these inhibitors continue to grow.

Increased understanding of the tumor microenvironment, the importance of molecular abnormalities, and the signaling pathways of cytokines has finally yielded more effective, tumor-specific therapies.

Topline data from the phase 3 ATLAS and ENVISION trials of UGN-102 showed a robust and consistent therapeutic profile when used for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer.

Positive topline results from the AGAVE-201 trial have led the companies to submit a biologics license application to the FDA by the end of 2023.

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted pet imaging agent in prostate cancer. The agent has now been added to the NCCN guidelines.

Primary results from the phase 1 COVALENT 101 study demonstrate the potential of BMF-219 to induce responses in patients with various relapsed or refractory leukemias/lymphomas, including acute myeloid leukemia.

According to data from the primary and updated analyses of the phase 2 DESTINY-Gastric02 study, trastuzumab deruxtecan is beneficial for patients with HER2-positive advanced gastric cancer.

This article explorex some of the more frequently encountered toxicities of FGFR inhibitors and their optimal management.

Niraparib as a monotherapy is supported as standard of care for a broad patient population with advanced ovarian cancer after first-line platinum-based chemotherapy.

Investigators do not believe the benefit-risk profile of Lonca R in previously untreated diffuse large B-cell lymphoma supports continuation of the LOTIS-9 trial.

Robert L. Ferris, MD, PhD, discussed the growing use of bispecific antibodies and how he expects to see more of these advances in the coming years.

Investigators are evaluating the efficacy and safety of selinexor vs placebo when used as a maintenance therapy for patients with p53 wild-type advanced or recurrent endometrial cancer.

Edwin Choy, MD, provides key recommendations for community oncologists treating patients with gastrointestinal stromal tumor.

Results from a subgroup analysis of the phase 3 SIENDO study show a survival advantage, signaling that tp53 may have predictive value for treatment with selinexor, in addition to its prognostic value.

Significant progression-free survival and overall survival benefits were demonstrated with rivoceranib plus camrelizumab for patients with unresectable hepatocellular carcinoma when used in the first-line setting.

Though the benefit of consolidative stem cell transplant for patients who received A+CHP appeared less pronounced vs those treated with the CHOP regimen, the method is still supported for patients with CD30-positive peripheral T-cell lymphomas.

In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.

Lucia Masarova, MD, PhD, discusses therapeutic options for patients with polycythemia vera who are refractory to hydroxyurea.

A total of 110 patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer have been enrolled in a phase 3 study evaluating cretostimogene grenadenorepvec.

During a Targeted Oncology Case-Based Roundtable event, Cristina Gasparetto, MD, discussed the case of a patient with stage I multiple myeloma and highlighted outcomes of the phase 3 BOSTON trial.

In an interview with Targeted Oncology, Omid Hamid, MD, discussed the efficacy of fianlimab in combination with cemiplimab for advanced melanoma. The results of the study show new possibilities for treating patients who have failed adjuvant anti PD-1 therapy.

Interim analysis results of the phase 3 PANOVA-3 trial in patients with unresectable, locally advanced pancreatic cancer support the company proceeds with the final analysis